1. Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial) 
Sonja Adebahr, MD, Marlene Hechtner, Nele Schräder, Tanja Schimek-Jasch, MD, Klaus Kaier, PhD, Viola Duncker-Rohr, MD, Eleni Gkika, MD, Felix Momm, MD, Jan Gaertner, MD, Gerhild Becker, MD, Anca-Ligia Grosu, MD, Ursula Nestle, MD 
Journal of Thoracic Oncology 
Volume 14, Issue 3, Pages (March 2019)
DOI: /j.jtho
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Quality of life (QoL) changes from before fractionated stereotactic body radiotherapy (SBRT) to 7 weeks after SBRT assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 (A, B) and the QLQ LC13 lung cancer-specific questionnaire (C) regarding n = 97 patients of the prospective STRIPE cohort of pulmonary SBRT patients who filled out at least one questionnaire. Change (Δ) of group mean post-SBRT and pre-SBRT values are presented, MID (grey bar) represents the minimal important difference of 10 points. Neither QoL/global health status (GHS), nor function scores, nor symptom scales revealed any clinically relevant changes during short-time follow-up after SBRT of pulmonary lesions. PF, physical function; RF, role function; EF, emotional function; CF, cognitive function; SF, social function; LoA, loss of appetite; FD, financial difficulties; PN, peripheral neuropathy; MID, minimally important differences.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Subgroup analyses for patients with pulmonary malignancies treated with fractionated stereotactic body radiotherapy (SBRT). Change (Δ) of individualized mean values, 7 weeks post-SBRT – pre-SBRT values for the five predefined quality of life (QoL) scales of interest (QoL/ global health status [GHS], emotional function [EF], physical function [PF], fatigue, and dyspnea) are presented for subgroups of predefined patient- and treatment-related factors: (A) baseline QoL/GHS; (B) Karnofsky Index (KI); (C) age; (D) sex; (E) diagnosis; (F) tumor localization; (G) patient-rated dyspnea assessed by the lung cancer specific module (LC13) of the European Organization for Research and Treatment of Cancer QoL Questionnaire; (H) physician-rated dyspnea; (I) Charlson comorbidity index (CCI); (J) size of planning target volume (PTV); and (K) applied dose. Minimally important difference (grey bar) represents a difference of 10 points. BED, biological effective dose.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 2
Subgroup analyses for patients with pulmonary malignancies treated with fractionated stereotactic body radiotherapy (SBRT). Change (Δ) of individualized mean values, 7 weeks post-SBRT – pre-SBRT values for the five predefined quality of life (QoL) scales of interest (QoL/ global health status [GHS], emotional function [EF], physical function [PF], fatigue, and dyspnea) are presented for subgroups of predefined patient- and treatment-related factors: (A) baseline QoL/GHS; (B) Karnofsky Index (KI); (C) age; (D) sex; (E) diagnosis; (F) tumor localization; (G) patient-rated dyspnea assessed by the lung cancer specific module (LC13) of the European Organization for Research and Treatment of Cancer QoL Questionnaire; (H) physician-rated dyspnea; (I) Charlson comorbidity index (CCI); (J) size of planning target volume (PTV); and (K) applied dose. Minimally important difference (grey bar) represents a difference of 10 points. BED, biological effective dose.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions